1-4

Watch podcasts based on our recent Meet the Expert Live Webinar Series: Rational Pharmacotherapy in the Treatment of Pain of Postherpetic Neuralgia. These cases are also available for viewing on portable media devices, such as Apple® iPod or iPhone®, or by subscribing via other podcast websites or programs.

Please select a podcast to view:



Now Playing:

Also See:

Subscribe to our podcasts
To subscribe to the podcast series, copy and paste the following link into your favorite podcast program, such as Apple® iTunes®:
Web Editorial Board
Gerald M. Aronoff, MD, DABPM, DABPN
Medical Director
Carolina Pain Associates
Charlotte, North Carolina
Adjunct Associate Professor
Duke University Medical Center
Department of Psychiatry, Pain Evaluation & Treatment Service
Durham, North Carolina

Christopher Gharibo, MD
Clinical Director of Pain Medicine
NYU—Langone Medical Center
Director of Chronic Pain Medicine
NYU—Hospital for Joint Diseases
New York, New York

Riad Laham, MD
Hillcrest Pain Management
Cleveland Clinic Health System
Cleveland, Ohio

Dennis J. Patin, MD
Division Chief
University of Miami
Sylvester Comprehensive Cancer Center
Department of Anesthesiology, Perioperative Medicine, and Pain Management
Miami, Florida

Joseph V. Pergolizzi, MD
Adjunct Assistant Professor
Johns Hopkins University School of Medicine Baltimore, Maryland
Senior Partner
Naples Anesthesia and Pain Associates
Naples, Florida




Important Safety Information

LIDODERM® (lidocaine patch 5%) is indicated for relief of pain associated with post-herpetic neuralgia. Apply only to intact skin.

LIDODERM is contraindicated in patients with a history of sensitivity to local anesthetics (amide type) or any product component.

Even a used LIDODERM patch contains a large amount of lidocaine (at least 665 mg). The potential exists for a small child or pet to suffer serious adverse effects from chewing or ingesting a new or used LIDODERM patch, although the risk with this formulation has not been evaluated. It is important for patients to store and dispose of LIDODERM out of reach of children, pets, and others.

Excessive dosing, such as applying LIDODERM to larger areas or for longer than the recommended wearing time, could result in increased absorption of lidocaine and high blood concentrations leading to serious adverse effects.

Avoid contact of LIDODERM with the eye. If contact occurs, immediately wash the eye with water or saline and protect it until sensation returns. Avoid the use of external heat sources as this has not been evaluated and may increase plasma lidocaine levels.

Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine, because of their inability to metabolize lidocaine normally. LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. LIDODERM should also be used with caution in pregnant (including labor and delivery) or nursing mothers.

Allergic reactions, although rare, can occur.

During or immediately after LIDODERM treatment, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours. Other reactions may include dizziness, headache and nausea.

When LIDODERM is used concomitantly with local anesthetic products, the amount absorbed from all formulations must be considered.

Immediately discard used patches or remaining unused portions of cut patches in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.

Before prescribing LIDODERM, please refer to the full Prescribing Information.

References

  1. Cluff RS, Rowbotham MC. Pain Caused by Herpes Zoster Infection. Neurol Clin. 1998;16(4):813-832.
  2. Weaver BA. The burden of herpes zoster and postherpetic neuralgia in the United States. J Am Osteopath Assoc.
  3. Population projections: US interim projections by age, sex, race, and Hispanic origin: 2000-2050. US Census Bureau Web site. http://www.census.gov/population/www/projections/usinterimproj/. Accessed October 9, 2008.
  4. Rowbotham MC. Postherpetic neuralgia. Semin Neurol. 1994;14(3):247-254. 2007;107(suppl 1):S2-S7.